Anti-PSMA Immunocytokine, IgG (2C9)-IL2

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-PSMA IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the PSMA as well as the biological activity of IL2. This antibody-cytokine fusion protein is an C-terminus interleukin-2 (IL2)-fused immunocytokine, exhibited enhanced cytotoxic activity against PSMA-expressing prostate cancer cells in the presence of PBMCs. It has a therapeutic potential for prostate cancer by stimulating lymphocyte-mediated antitumor cytotoxicity. This immunocytokine was designed for treating prostate cancer. http://www.creativebiolabs.net/Anti-PSMA-Immunocytokine-IgG-2C9-IL2-22472.htm